1.An analysis of clinical efficacy of edaravone combined with β-aescin sodium for treatment of elderly patients with acute cerebral hemorrhage based on dynamic changes of vascular endothelial growth factor and inflammatory factor levels
Xiaoyan XIE ; Xiuzhi HUA ; Jiangqing SONG
Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care 2017;24(1):28-31
Objective To investigate the clinical efficacy of edaravone combined with β-aescin sodium for treatment of elderly patients with acute cerebral hemorrhage,and the dynamic changes of tumor necrosis factor-α(TNF-α) and C-reactive protein (CRP),vascular endothelial growth factor (VEGF) levels in serum in such patients before and after treatment.Methods A total of 99 elderly patients with acute cerebral hemorrhage admitted to Henan Nanyang Second General Hospital from April 2014 to February 2016 were enrolled,and they were divided into control group (49 cases) and observation group (50 cases) according to the random digital table.Conventional treatment were given to both groups,patients in the observation group were added with edaravone 30 mg intravenous drip,2 times a day and β-aescin 20 mg intravenous drip,once daily.After treatment for consecutive 2 weeks,the clinical effect and neurological deficit score (NDS) were observed in the two groups;serum CRP levels were detected by immunonephelometry;TNF-αα and VEGF were detected by enzyme linked immunosorbent assay (ELISA).The changes of CRP,VEGF,TNF-α levels and incidence of adverse reactions before and after treatment were compared between the two groups.Results The levels of NDS,CRP,VEGF and TNF-α in both groups after treatment were significantly lower than those before treatment,and the degrees of decrease in treatment group were more significant than those in control group [NDS score:13.01 ± 1.37 vs.20.63 ± 1.68,CRP (mg/L):8.05 ± 3.97 vs.10.04 ± 4.17,VEGF (ng/L):97.25 ± 13.73 vs.116.43 ± 14.10,TNF-α (ng/L):8.15 ± 2.52 vs.11.54 ± 2.22,all P < 0.05];the total effective rate in observation group was significantly higher than that in control group [92.00% (46/50) vs.77.55% (38/49),P < 0.05].The difference of incidence of adverse reaction between observation group and control group was not statistically significant [4.00% (2/50) vs.8.16% (4/49),P > 0.05].Conclusions Edaravone combined with β-aescin sodium for treatment of elderly patients with acute cerebral hemorrhage can effectively promote the recovery of neurological function,and its rolemight be related to the regulation of the levels of CRP,TNF-α and VEGF.
2. Biological markers of Kawasaki disease
Xiaoying LU ; Xiuzhi ZHAO ; Xiaomei ZHANG ; Hua ZHU
International Journal of Pediatrics 2020;47(1):14-17
Kawasaki disease is an acute, self-limited vasculitis, which mainly affects infants and children under the age of 5 years.The main complication is coronary artery disease.Untreated Kawasaki disease leads to varying degrees of coronary artery damage in about 15%-25% of patients.The incidence of Kawasaki disease is increasing year by year, which has become one of the main causes of acquired heart disease in children and has a serious impact on the quality of life for children and adults.The cause of Kawasaki disease is not clear.In recent years, it has become a hot topic for pediatric cardiomyovasculopathy.With the development of molecular biology and gene technology, more and more sensitive biomarkers of Kawasaki disease have been found.This article will review the sensitive biomarkers of Kawasaki disease.